GT Biopharma Inc. receives Investment Bank Analyst Rating Update
- ByInvesting.com-
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GT Biopharma Inc (GTBP)
NASDAQ
Symbol | Exchange | Currency |
|---|
2.75
+0.15(+5.77%)
After Hours
2.75
0.00(0.00%)
- Real-time Data
- Volume:138,326
- Day's Range:2.46 - 2.79
- 52 wk Range:1.53 - 9.70
GTBP Overview
- Prev. Close
- 2.6
- Day's Range
- 2.46-2.79
- Revenue
- -
- Open
- 2.61
- 52 wk Range
- 1.53-9.7
- EPS
- -1
- Volume
- 138,326
- Market Cap
- 83.88M
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 183,050
- P/E Ratio
- -
- Beta
- 0.46
- 1-Year Change
- -74.56%
- Shares Outstanding
- 30,500,717
- Next Earnings Date
- Nov 09, 2022
What is your sentiment on GT Biopharma?
or
Market is currently closed. Voting is open during market hours.
GT Biopharma Inc Company Profile
GT Biopharma Inc Company Profile
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Sell | Strong Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 118.16 | 118.66 | 117.50 | +0.45 | +0.38% | 1.64M | NYSE | |||
| 8.37 | 8.47 | 8.16 | +0.24 | +2.95% | 6.64M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 1.205 | 1.23 | 1.19 | -0.0050 | -0.41% | 2.57M | NYSE | |||
| 32.74 | 32.75 | 31.69 | +0.89 | +2.81% | 4.93M | NYSE | |||
| 1.085 | 1.10 | 1.01 | +0.0650 | +6.37% | 306.83K | NYSE | |||
| 3.60 | 3.65 | 3.54 | +0.080 | +2.27% | 10.10M | NYSE | |||
| 46.26 | 46.28 | 45.16 | +1.36 | +3.03% | 1.89M | NYSE | |||
| 50.90 | 51.04 | 49.74 | -0.20 | -0.39% | 3.16M | NYSE | |||
| 50.11 | 50.39 | 48.55 | +1.82 | +3.77% | 25.57M | NYSE | |||
| 43.51 | 43.66 | 43.24 | -0.11 | -0.25% | 5.55M | NYSE | |||
| 122.65 | 122.65 | 120.40 | +2.83 | +2.36% | 15.67M | NASDAQ | |||
| 0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
| 128.20 | 128.52 | 126.71 | +1.21 | +0.95% | 768.09K | NYSE | |||
| 81.24 | 81.24 | 80.44 | +0.54 | +0.67% | 1.27M | NYSE |
- Dec 30, 2021, 18:01Pipeline of this company is terrific, one of the most promising on the board. Average one year target price according to qualified analysts panel is 25 USD (Bloomberg). Market is ignoring all this evidence. To me looks alike a strong buy down here.
- Dec 31, 2020, 24:36wait for nasdaq....or phase 1....well
- Dec 03, 2020, 21:06Any thought on this